Oncimmune is a leading early cancer detection company. It has pioneered the development of autoantibody assay technologies that have the potential to allow cancer detection up to four years earlier than other methods and can be applied to a wide range of solid tumour types.
In 2009, Oncimmune launched its proprietary platform technology for early cancer detection, called EarlyCDT®. The first test, EarlyCDT®-Lung, was commercialised in 2009 and test marketed until 2012, at which time it launched nationally across the US and since then over 150,000 commercial tests have been sold. It is now available through physicians in the US and also privately in the UK and other regions.
EarlyCDT-Lung is a simple blood test which is ordered by a doctor to aid in the risk assessment and early detection of lung cancer in high-risk patients and to stratify indeterminate pulmonary nodules for the risk of malignancy.
The Company also aims to develop the test for other cancers, in particular liver and ovarian cancers where EarlyCDT tests cancer are undergoing validation.
Oncimmune Ltd is headquartered in Nottingham, UK and testing is conducted in our CLIA-approved laboratory, based in De Soto, Kansas, USA